S941
Clinical - Non-malignant & functional radiotherapy
ESTRO 2026
volumes (TV), radiotherapy technique, dose prescription concepts, dosimetry, and motion management was evaluated. Results: 67 patients (59 male, 7 female, 1 trans-female, age mean (67±9) years, range 42-85 years) with refractory monomorphic VT after no Catheter Ablation (CA) (6%), 1-2 CA (47%) or >2 CA (47%) and failed antiarrhythmic drug therapy were included. The time between the first ICD (implantable cardioverter defibrillator; 91% conventional and 6% S-ICD) implantation and treatment was 64 months (median, range 3 days - 228 months). 7% had an additional LVAD (Left Ventricular Assisting Device) and 3% had no implanted device. The ECOG performance status before STAR was 0 (9%), 1 (2%), 2 (32%), 3 (20%) and 4 (19%) and the NYHA class was I (9%), II (35%), III (44%) and IV (12%), respectively. Median left ventricular ejection fraction (LVEF) was 34% (range 10-60%), 59% of the patients had ischemic and 41% non-ischemic cardiomyopathy. Additional comorbidities included coronary heart disease in 40%, diabetes in 13%, previous myocardial infarction in 18%, myocarditis in 6% and valve anomalies in 22%. Median time between last CA and STAR was 35 days (range 0-567 days). 19% of the patients were treated less than 14 days after CA indicating an emergency indication (e.g. VT-storm). Information about TV definition, dose prescription, and implementation of STAR is summarized in Table 1. Cumulative dose volume histograms (DVH) for PTV and left ventricle are shown in Figure 2. For each dose the median volume (red line), interquartile range (blue area) and range (grey area) of volumes are illustrated.
Figure 2 Conclusion: This analysis illustrates the spectrum of STAR indications and treatment techniques in Germany. In certain aspects of the treatment, such as CTV definition and contouring, treatment goals, prescription dose, and treatment techniques, harmonization is already apparent, while patient selection and dose inhomogeneity are still largely based on the individual clinicians’ decision. The evaluation of the full STOPSTORM database with follow-up data will open more opportunities for harmonization and optimization soon. Keywords: STAR, VT, STOPSTORM Digital Poster 661 Stereotactic Radiosurgery for Circumscribed Choroidal Hemangioma: A Single-Center Experience Alper Kahvecioglu 1 , Irem Koc 2 , Mustafa Cengiz 1 , Ayca Yilmaz 2 , Ekim Gumeler 3 , Hayyam Kiratli 2 , Gozde Yazici 1 1 Radiation Oncology, Hacettepe University, Ankara, Turkey. 2 Ophtalmology, Hacettepe University, Ankara, Turkey. 3 Radiology, Hacettepe University, Ankara, Turkey Purpose/Objective: To assess the efficacy of stereotactic radiosurgery (SRS) in improving visual and anatomical outcomes in patients with symptomatic circumscribed choroidal
Table 1
Made with FlippingBook - Share PDF online